Genentech Reorganization Signals Shift To New Model Under Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s Soriot will take over as CEO of Genentech, while key members of Genentech’s management will take on advisory roles or depart.
You may also be interested in...
Clinical Development Setbacks, Pricing Pressures Hit Roche
Recent setbacks for two of its most important pipeline projects, as well as a tougher pricing environment in key Western countries, will take a toll on Roche in 2010 and beyond, company executives told analysts during a half-year earnings call on July 22
Clinical Development Setbacks, Pricing Pressures Hit Roche
Recent setbacks for two of its most important pipeline projects, as well as a tougher pricing environment in key Western countries, will take a toll on Roche in 2010 and beyond, company executives told analysts during a half-year earnings call on July 22
Clinical Development Setbacks, Pricing Pressures Hit Top, Bottom Lines at Roche
"The financial crisis has arrived for the pharmaceutical industry," says CEO Severin Schwan.